{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=85", "query": { "condition": "Cancer", "page": 85 }, "page_size": 10 }, "pagination": { "page": 85, "page_size": 10, "total_count": 50382, "total_pages": 5039, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=86&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=84&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T07:01:52.033Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00251446", "title": "A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Vinflunine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veeda Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2005-10", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2012-05-11", "last_synced_at": "2026-11-03T07:01:52.033Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00251446" }, { "nct_id": "NCT02558803", "title": "HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Human Papilloma Virus Infection Type 11", "Human Papilloma Virus Infection Type 16", "Human Papilloma Virus Infection Type 18", "Human Papilloma Virus Infection Type 6", "Cervical Cancer", "Genital Warts", "Oropharyngeal Cancer" ], "interventions": [ { "name": "Simple Reminder", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Regenstrief Institute, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "11 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "11 Years to 17 Years" }, "enrollment_count": 1305, "start_date": "2015-02", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2016-05-25", "last_synced_at": "2026-11-03T07:01:52.033Z", "location_count": 5, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02558803" }, { "nct_id": "NCT04659603", "title": "Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer Metastatic", "Pancreatic Carcinoma Metastatic" ], "interventions": [ { "name": "tusamitamab ravtansine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-03-29", "completion_date": "2025-01-19", "has_results": true, "last_update_posted_date": "2025-10-01", "last_synced_at": "2026-11-03T07:01:52.033Z", "location_count": 3, "location_summary": "Orlando, Florida • Boston, Massachusetts • Madison, Wisconsin", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04659603" }, { "nct_id": "NCT03907527", "title": "Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Refractory Fallopian Tube Carcinoma", "Refractory Ovarian Carcinoma", "Refractory Primary Peritoneal Carcinoma", "Stage III Fallopian Tube Cancer AJCC V8", "Stage III Ovarian Cancer AJCC V8", "Stage III Primary Peritoneal Cancer AJCC V8", "Stage IIIA Fallopian Tube Cancer AJCC V8", "Stage IIIA Ovarian Cancer AJCC V8", "Stage IIIA Primary Peritoneal Cancer AJCC V8", "Stage IIIA1 Fallopian Tube Cancer AJCC V8", "Stage IIIA1 Ovarian Cancer AJCC V8", "Stage IIIA2 Fallopian Tube Cancer AJCC V8", "Stage IIIA2 Ovarian Cancer AJCC V8", "Stage IIIB Fallopian Tube Cancer AJCC V8", "Stage IIIB Ovarian Cancer AJCC V8", "Stage IIIB Primary Peritoneal Cancer AJCC V8", "Stage IIIC Fallopian Tube Cancer AJCC V8", "Stage IIIC Ovarian Cancer AJCC V8", "Stage IIIC Primary Peritoneal Cancer AJCC V8", "Stage IV Fallopian Tube Cancer AJCC V8", "Stage IV Ovarian Cancer AJCC V8", "Stage IV Primary Peritoneal Cancer AJCC V8", "Stage IVA Fallopian Tube Cancer AJCC V8", "Stage IVA Ovarian Cancer AJCC V8", "Stage IVA Primary Peritoneal Cancer AJCC V8", "Stage IVB Fallopian Tube Cancer AJCC V8", "Stage IVB Ovarian Cancer AJCC V8", "Stage IVB Primary Peritoneal Cancer AJCC V8" ], "interventions": [ { "name": "PRGN-3005 UltraCAR-T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Precigen, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 71, "start_date": "2019-04-30", "completion_date": "2028-11-15", "has_results": false, "last_update_posted_date": "2024-11-08", "last_synced_at": "2026-11-03T07:01:52.033Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Seattle, Washington", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03907527" }, { "nct_id": "NCT06070870", "title": "Health Education Approach to Lung Screening", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Patient Navigation", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 675, "start_date": "2023-10-10", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-11-03T07:01:52.033Z", "location_count": 3, "location_summary": "Carrboro, North Carolina • Charleston, South Carolina • Richmond, Virginia", "locations": [ { "city": "Carrboro", "state": "North Carolina" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06070870" }, { "nct_id": "NCT07392970", "title": "Motixafortide for MRD Sensitization in AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Measurable Residual Disease" ], "interventions": [ { "name": "Motixafortide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2026-07-23", "completion_date": "2030-02-02", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-11-03T07:01:52.033Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07392970" }, { "nct_id": "NCT00397969", "title": "Improving the Frequency of Colonoscopy in Patients With a Previous Colorectal Polyp", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Colorectal Cancer", "Precancerous Condition" ], "interventions": [ { "name": "counseling intervention", "type": "OTHER" }, { "name": "screening colonoscopy", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Harvard Medical School (HMS and HSDM)", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 800, "start_date": "2005-02", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2013-12-19", "last_synced_at": "2026-11-03T07:01:52.033Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00397969" }, { "nct_id": "NCT00026169", "title": "Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Neoplasm", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 69, "start_date": "2001-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-10", "last_synced_at": "2026-11-03T07:01:52.033Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00026169" }, { "nct_id": "NCT00301769", "title": "SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Blastic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes" ], "interventions": [ { "name": "SJG-136", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2005-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-11-03T07:01:52.033Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00301769" }, { "nct_id": "NCT01842789", "title": "Post Market Evaluation of Acessa With TAG", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Uterine Fibroids" ], "interventions": [ { "name": "Acessa Procedure", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Acessa Health, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "18 Years to 55 Years · Female only" }, "enrollment_count": 18, "start_date": "2013-04", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2017-08-18", "last_synced_at": "2026-11-03T07:01:52.033Z", "location_count": 1, "location_summary": "San Ramon, California", "locations": [ { "city": "San Ramon", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01842789" } ] }